Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
BACK TO LIST

Laboratory Report

Patient
Name: Nilsson, , Khalid,
DOB: 10-APR-1952 (Age: 73)
Gender: male
Address:
Gengränd 482
691 31 Karlskoga (Sweden)
ID: 8339-594203-6 (ECI)
Report
Date: 03-SEP-2019
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Karlskoga Lasarett
691 31 Karlskoga (Sweden)
Specimen
Collected: 02-SEP-2019

Chemistry

Test 03-SEP-2019 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 6.3 4.5 - 6.4 %
Glucose [Mass/volume] in Blood 86.6 70 - 99 mg/dL
Urea nitrogen [Mass/volume] in Blood 9.9 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 0.9 0.9 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 9.6 8.6 - 10.2 mg/dL
Sodium [Moles/volume] in Blood 140.2 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.6 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 105.6 98 - 108 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 25.0 22 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 156.2 0 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 124.3 40 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 101.4 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 29.9 L 40 - 100 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
All measured parameters are within normal limits except for a low HDL cholesterol (29.9 mg/dL), which is a cardiovascular risk factor. Glycemic control (HbA1c 6.3%) is at the upper end of normal, suggesting prediabetes. Renal and electrolyte parameters are normal. Recommend addressing low HDL through lifestyle modification and monitoring glycemic status.